Effect of Pembrolizumab (Keytruda®) on Biomarkers in Early Breast Cancer.

Clinical trial NCT03197389 · COMPLETED

Trial details

NCT number: NCT03197389
Sponsor: Universitaire Ziekenhuizen KU Leuven
Status: COMPLETED
Phase: Early Phase 1
Study type: INTERVENTIONAL

Breast Cancer Triple Negative Breast Cancer Hormone Receptor Negative Neoplasm

Start date: 2018-01-18
Primary completion: 2020-03-31
Enrollment: 54

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.